- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07852728
HBOT Effects on First Responders' Cognition and Well-Being
Changes in Cognitive Functioning, Psychological Well-Being, and Quality of Life Following Hyperbaric Oxygen Therapy in First Responders
The goal of this study is to examine changes in cognitive functioning and post-concussive symptoms following hyperbaric oxygen therapy (HBOT) in current and former first responders with a history of traumatic brain injury. The main questions it aims to answer are:
- Do cognitive functioning and post-concussive symptoms change after 40 HBOT sessions?
- Do symptoms of PTSD, depression, and anxiety, or quality of life, change after treatment?
Approximately 54 participants will:
- Complete medical and behavioral health screening.
- Complete cognitive tests and questionnaires before and after treatment.
- Receive 40 HBOT sessions at 2.0 atmospheres absolute (ATA), twice daily with at least four hours between sessions.
All participants will receive HBOT. There is no comparison group, so the study cannot determine whether HBOT caused any observed changes.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
This prospective, single-arm study will examine changes in cognitive functioning and post-concussive symptoms following hyperbaric oxygen therapy (HBOT) in approximately 54 current or former first responders with a history of traumatic brain injury (TBI). Secondary outcomes include symptoms of post-traumatic stress disorder (PTSD), depression, and anxiety, as well as quality of life.
After providing informed consent, participants will undergo medical and behavioral health screening to determine eligibility for HBOT. Eligible participants will complete baseline cognitive testing and questionnaires measuring post-concussive symptoms, psychological symptoms, and quality of life. These assessments will be repeated after treatment.
Participants will receive 40 HBOT sessions in a multiplace chamber at 2.0 atmospheres absolute (ATA). Each session will include two 30-minute periods of breathing 100% oxygen separated by a 5-minute air break. Sessions will take place twice daily, Monday through Friday, with at least four hours between sessions. A physician will prescribe and oversee treatment, and trained hyperbaric personnel will operate the chamber and monitor participants.
Changes between baseline and post-treatment assessments will be analyzed within participants. The study will also explore whether demographic or clinical characteristics are associated with the magnitude of change. All participants will receive HBOT; there is no randomized or untreated comparison group. As a result, the study can describe changes observed following treatment but cannot establish that HBOT caused those changes.
Studientyp
Einschreibung (Geschätzt)
Phase
- Phase 2
Kontakte und Standorte
Studienkontakt
- Name: Troy Nickel, Ph.D.
- Telefonnummer: 208-813-9541
- E-Mail: tnickel@shwidaho.org
Studienorte
-
-
Idaho
-
Boise, Idaho, Vereinigte Staaten, 83716
- Rekrutierung
- Summit Hyperbarics and Wellness
-
Kontakt:
- Troy Nickel, Ph.D.
- Telefonnummer: 208-813-9541
- E-Mail: tnickel@shwidaho.org
-
Hauptermittler:
- Steve Wyman, MD
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion criteria
- Adults aged 18 to 75 years.
- Current or former first responder.
- Clinically diagnosed with a traumatic brain injury (TBI) and current or persistent post-concussive syndrome, as determined by a qualified health care professional.
- Participants with comorbid PTSD, depression, or anxiety may be enrolled if all other eligibility criteria are met; these symptoms will be assessed as secondary/exploratory outcomes.
- Ability to provide informed consent, including the ability to read, understand, and voluntarily sign the informed consent document.
- Completion of baseline cognitive and psychological assessment measures as part of study enrollment procedures.
- Presence of clinically significant symptoms resulting in functional impairment in occupational, social, or other key areas of functioning, as determined by clinical evaluation.
- Sexually active female participants of childbearing potential and sexually active male participants with female partners of childbearing potential must agree to use an acceptable method of contraception for the duration of the study and for 30 days following the final HBOT session.
- Stable regimen of psychoactive medications (if applicable), including antidepressants, anxiolytics, antipsychotics, stimulants, and mood stabilizers, for a clinically appropriate stabilization period prior to enrollment, as determined by the study physician.
Exclusion criteria
- Untreated pneumothorax
- History of spontaneous pneumothorax
- Severe sinus infection
- Upper respiratory infection
- Asymptomatic pulmonary lesions on chest x-ray
- Uncontrollable high fever (greater than 39C)
- History of chest or ear surgery
- Congenital spherocytosis
- Any anemia or blood disorder
- Any convulsive disorder
- History of optic neuritis or sudden blindness
- Middle ear infection
- Diabetes mellitus (insulin therapy)
- The participant is pregnant or lactating
- Nicotine use/substance use/addiction
- Acute Hypoglycemia
- Diagnosed Chronic Obstructive Pulmonary Disease (COPD) and Emphysema
- Presenting with symptoms of cough, congestion, vomiting, diarrhea, or open wounds.
- Active malignancy
- Current manic, delusional, or psychotic episodes
- Serious/current suicidal ideations
- Severe or unstable physical disorders or major cognitive deficits
- Inability to attend scheduled clinic visits or comply with study protocols.
- Treated with HBOT for any reason prior to study enrollment.
- Non-English speakers
- History of retinal repair, including laser photocoagulation or retinal detachment surgery.
- History of middle ear surgery, including tympanoplasty, mastoidectomy, or pressure equalization tube placement.
- Age greater than 75 years.
- Use of any of the following medications during the study period: Anti-metabolites (e.g., methotrexate, azathioprine); Chemotherapuetic agents (e.g., cyclophosphamide, cisplatin); Mafenide acetate e.g., Sulfamylon); Disulfiram (e.g, Antabuse); Peripheral vasodilators known to interact with oxygen exposure (e.g., nitroglycerin); and Antibacterial drugs with known HBOT interaction risks.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Hyperbaric Oxygen Therapy
Participants in this arm will receive 40 hyperbaric oxygen therapy (HBOT) sessions at 2.0 atmospheres absolute (ATA). Sessions will occur twice daily, Monday through Friday, with at least four hours between sessions. Cognitive functioning, post-concussive symptoms, psychological symptoms, and quality of life will be assessed before and after treatment. |
Participants in this arm will receive 40 hyperbaric oxygen therapy (HBOT) sessions at 2.0 atmospheres absolute (ATA). Sessions will occur twice daily, Monday through Friday, with at least four hours between sessions. Cognitive functioning, post-concussive symptoms, psychological symptoms, and quality of life will be assessed before and after treatment. |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Change in NeuroTrax Global Cognitive Score
Zeitfenster: Baseline and after completion of 40 HBOT sessions (approximately 4 weeks).
|
Change in Global Cognitive Score from baseline to completion of 40 HBOT sessions. |
Baseline and after completion of 40 HBOT sessions (approximately 4 weeks).
|
|
Change in Rivermead Post-Concussion Symptoms Questionnaire (RPQ) score
Zeitfenster: Baseline and after completion of 40 HBOT sessions (approximately 4 weeks).
|
Change in post-concussive symptom score from baseline to completion of 40 HBOT sessions. |
Baseline and after completion of 40 HBOT sessions (approximately 4 weeks).
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Change in PTSD Checklist for DSM-5 (PCL-5) score
Zeitfenster: Baseline and after completion of 40 HBOT sessions (approximately 4 weeks).
|
Change in PTSD symptom score from baseline to completion of 40 HBOT sessions. |
Baseline and after completion of 40 HBOT sessions (approximately 4 weeks).
|
|
Change in Patient Health Questionnaire-9 (PHQ-9) score
Zeitfenster: Baseline and after completion of 40 HBOT sessions (approximately 4 weeks).
|
Change in depression symptom score from baseline to completion of 40 HBOT sessions. |
Baseline and after completion of 40 HBOT sessions (approximately 4 weeks).
|
|
Change in Generalized Anxiety Disorder-7 (GAD-7) score
Zeitfenster: Baseline and after completion of 40 HBOT sessions (approximately 4 weeks).
|
Change in anxiety symptom score from baseline to completion of 40 HBOT sessions. |
Baseline and after completion of 40 HBOT sessions (approximately 4 weeks).
|
|
Change in World Health Organization Quality of Life-BREF (WHOQOL-BREF) domain scores
Zeitfenster: Baseline and after completion of 40 HBOT sessions (approximately 4 weeks).
|
Change in quality-of-life scores from baseline to completion of 40 HBOT sessions. |
Baseline and after completion of 40 HBOT sessions (approximately 4 weeks).
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: Steve Wyman, MD, Summit Hyperbarics and Wellness
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Trauma- und stressbedingte Störungen
- Erkrankungen des Gehirns
- Erkrankungen des zentralen Nervensystems
- Erkrankungen des Nervensystems
- Psychische Störungen
- Wunden und Verletzungen
- Verhaltenssymptome
- Kraniozerebrales Trauma
- Trauma, Nervensystem
- Kopfverletzungen, geschlossen
- Wunden, nicht durchdringend
- Hirnverletzungen
- Belastungsstörungen, traumatisch
- Gehirnerschütterung
- Verhalten
- Hirnverletzungen, traumatisch
- Angststörungen
- Depression
- Post-Concussion-Syndrom
- Belastungsstörungen, posttraumatisch
- Kampfstörungen
- Therapeutika
- Atemtherapie
- Sauerstoffinhalationstherapie
- Hyperbarische Sauerstoffversorgung
Andere Studien-ID-Nummern
- HBOT-FR-2026-001
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
There is no current plan to share IPD outside the study team. Given the relatively small sample of first responders and the sensitive clinical and occupational information collected, sharing participant-level data could increase the risk of re-identification. Study findings will be reported in aggregate.
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .